How many podcasts discuss a Kardashian, drug pricing, and readmission penalties-all in the same episode? We welcome guest Aaron Kesselheim, from Harvard Medical School, and the Department of Health Policy and Management at Harvard’s T.H. Chan School of Public Health. Aaron is a prolific and insightful scholar whose work has influenced policy makers globally.
To start the packed show, Nic and Frank discussed a new study of ACOs, proposed budget cuts for AHRQ, worry over unintended consequences of readmission penalties, and EHR gag clauses (and developer codes of conduct). With Aaron’s help we discussed Kim Kardashian’s FDA feud over stealth marketing of an anti-nausea drug, the FDA guidance on limited character social media marketing, the nomination of the new FDA Commissioner, and how we could tackle high drug prices using Sovaldi as an example.
Show notes and more are at TWIHL.com. If you have comments, an idea for a show or a topic to discuss you can find us on twitter @nicolasterry @FrankPasquale @WeekInHealthLaw